systematic review of all RCTs found no effects of n-3 PUFAs on effects on mortality or CV events. 1 The results of very recent large RCTs-VITAL and REDUCE-IT-do not fully resolve that controversy. 3, 4 VITAL placebo-controlled study involved 25 871 participants randomly assigned to marine n-3 fatty acids (at a dose of 1 g/day) in the primary prevention of CV disease and cancer ( Table 1) .
3 After a median follow-up of 5.3 years, no beneficial effects on major cardiovascular events (MACE) or cancer were demonstrated. Interestingly, in subgroup analysis in individuals with low consumption of fish during the trial (<1.5 fish servings) there was a significant 19% reduction of MACE. Secondary analysis also showed significant 28% reduction of total myocardial infarctions. Of note, the absolute risk reduction was small (0.5%). 3 However, as there was no effect of the treatment on the primary endpoint of the trial, such positive signals can only be viewed as hypothesis generating.
On the contrary, REDUCE-IT trial demonstrated remarkably positive results of n-3 PUFAs intervention. In this trial, 8179 patients with established CV disease or with diabetes and other risk factors were followed for a median of 4.9 years. Patients had moderately elevated triglyceride levels (median 216 mg/dL). 4 Apart from the type of patients, there were also other differences between the studies (Table 1) . Firstly, only pure ethyl ester of eicosapentaenoic acid (EPA) was used. Secondly, the dose was much higher-4 g/day. Compared to the mineral oil which was used as placebo in the trial, the treatment with EPA resulted in 19% reduction in triglyceride levels and 25% reduction of MACE. 4 Based on the last two trials with n-3 PUFAs it is clear that, there are gaps in our knowledge that make interpretation of that studies difficult, namely the exact mechanisms of potential beneficial effects, the proper dose, and the optimal target population ( Table 2 ). It might be speculated, based on previous data and REDUCE-IT trial, that triglyceride lowering is responsible for the beneficial action in EPA. 4, 5 However, according to
Mendelian randomization studies to get such a positive result as in REDUCE-IT trial, triglycerides should be lowered by 60-80%. 5 Therefore, there is serious need for additional mechanistic trials will provide further insights into the pleiotropic effects of n-3 PUFAs. Available data suggest PUFAs can protect against vascular calcification through the G-protein coupled receptor ChemR23 for resolvin E1, the omega-3-derived lipid mediator, which induces the resolution of vascular inflammation. 8 Emerging lines of evidence strongly support the anti-inflammatory role of n-3 PUFA. 2, 4 In REDUCE-IT trial, high-dose EPA treatment resulted in 22% reduction of C-reactive protein as compared to placebo. 4 This observation is supported by data numerous epidemiological studies which showed that the high intake of n-3 PUFAs is associated with decreased inflammation. 2 Eicosanoids derived from the EPA can down-regulate the biosynthesis of PGE 2 . Moreover, the antiinflammatory effects of n-3 PUFAs are also related to competition between EPA and arachidonic acid as substrates for cyclooxygenases and to prevention of the conversion of arachidonic acid into potent proinflammatory eicosanoids. Furthermore, n-3 PUFAs can serve as alternative substrates to produce less potent mediators, including 3-series prostaglandins and thromboxanes, and 5-series leukotrienes. Experimental studies showed that EPA and docosahexaenoic acid (DHA) are also substrates for production of pro-resolving lipid mediators such as resolvins, maresins, and protectins. 2 The further studies should clarify which of the effects plays a central role in the clinical benefit of n-3 PUFAs. Our previous studies suggested that beneficial effects of n-3 PUFAs administration (1 g EPA/DHA) include also antiplatelet and antithrombotic effects. We demonstrated that n-3 PUFAs added to standard dual antiplatelet therapy after percutaneous coronary intervention in patients with stable angina improved platelet response to clopidogrel. 9 Moreover, we found that fibrin clots formed from plasma of those patients who received n-3 PUFAs had a less compact structure, that was less resistant to lysis. 10 Additionally, n-3 PUFA intake in our study reduced thrombin formation, oxidative stress, and lipoprotein-associated phospholipase A 2 determined in circulating blood. 10, 11 The mechanisms of potentially important favourable antithrombotic effects of omega-3 PUFAs are complex. It has been shown that alteration of fatty acid composition can alter not only platelet membrane permeability, but also modulate function and activity of membrane receptors and transporters. 9 Omega-3 PUFAs may also lower thromboxane A 2 production because epoxidation and hydroxylation of both arachidonic acid and PUFAs are catalysed by cytochrome P-450. 9 Additionally, n-3 PUFAs can alter platelet function, thorough non-genomic effects of nuclear receptors, in particular peroxisome proliferator-activated receptors (a and b) and retinoid X receptor. 12 Moreover, as thrombin is a potent platelet agonist, decreased thrombin generation induced by n-3 PUFA is also likely to contribute to antiplatelet effects of those agents. 10 We have recently published the results of a study on patients with diabetes and atherosclerotic disease where we used a higher dose (2.4 g EPA/DHA) of n-3 PUFAs. Unfortunately, we were not able to demonstrate any effect of such a treatment on platelet function, coagulation, endothelial function, metabolic status, or inflammatory biomarkers, despite beneficial triglycerides' reduction. 13, 14 It might be speculated, that the procoagulant state related to DM2 may be so potent that it cannot be attenuated by the effects of n-3 PUFAs added on top optimal medical therapy. In summary, the conflicting results of both clinical outcome and mechanistic studies on the effects on n-3 PUFAs highlight the need of understanding the role of target population in such trials, dose and formulation of n-3 PUFAs.
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hsCRP, high sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule 1; IL-6, interleukin 6; JELIS, effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients study; LP-PLA2, phospholipase A2; NO, nitric oxide; oxLDL, oxidized low-density lipoprotein.
